Telix Pharmaceuticals

TLX

Market cap $2.55B

Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript

Telix Pharmaceuticals (TLX) maintains a "Buy" rating, driven by robust revenue growth and multiple late-stage oncology assets. TLX reported FY2025 revenue of $804 million, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622 million. Lead asset TLX591-Tx advances in phase 3 for mCRPC, while TLX250-Tx targets ccRCC in both monotherapy and combination trials.

MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry1, defining the potential prognostic value of PSMA-PET2 imaging through artificial intelligence (AI).

Telix's revenue grew by 56% in 2025. The Australian company develops drugs that can both detect and treat cancers.

Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025.

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate.

Telix Pharmaceuticals Limited (NASDAQ: TLX), a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue.

Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit.